Sectors
VOR
Vor Biopharma Inc.
23.29
1 x 22.76
1 x 23.40
bid
ask
+
0.95
4.25%
45 @ 04:00 PM
23.00 -0.29 (1.25%)
| Ytd | 78.06% | |
| 1y | -42.35% |
21.80
day range
23.57
6.50
52 week range
50.20
| Open | 22.01 | Prev Close | 22.34 | Low | 21.80 | High | 23.57 | Mkt Cap | 1.26B |
| Vol | 933.31K | Avg Vol | 1.17M | EPS | -3.16 | P/E | -7.37 | Forward P/E | -6.11 |
| Beta | 1.73 | Short Ratio | 5.77 | Inst. Own | 83.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 18.21 | 200-d Avg | 15.26 | 1yr Est | 39.00 |
| Income Statement | |||
| Operating Expenses | 47.85M | ||
| Research and Development Expense | 25.92M | ||
| Selling, General and Administrative Expense | 21.93M | ||
| Operating Income | -47.85M | ||
| Net Income | -62.81M | ||
| Net Income Common Stock | -62.81M | ||
| Net Income Common Stock (USD) | -62.81M | ||
| Consolidated Income | -62.81M | ||
| Earnings per Basic Share | -1.16 | ||
| Earnings per Basic Share (USD) | -1.16 | ||
| Earnings per Diluted Share | -1.16 | ||
| Earning Before Interest & Taxes (EBIT) | -62.81M | ||
| Earning Before Interest & Taxes (USD) | -62.81M | ||
| Weighted Average Shares | 54.30M | ||
| Weighted Average Shares Diluted | 54.30M | ||
| Balance Sheet | |||
| Cash and Equivalents | 108.02M | ||
| Cash and Equivalents (USD) | 108.02M | ||
| Investments | 358.27M | ||
| Investments Current | 358.27M | ||
| Current Assets | 475.11M | ||
| Property, Plant & Equipment Net | 3.37M | ||
| Total Assets | 481.05M | ||
| Debt Current | 335.00K | ||
| Total Debt | 2.88M | ||
| Current Liabilities | 24.81M | ||
| Debt Non-Current | 2.54M | ||
| Total Liabilities | 681.25M | ||
| Accumulated Retained Earnings (Deficit) | -1.44B | ||
| Accumulated Other Comprehensive Income | -922.00K | ||
| Shareholders Equity | -200.20M | ||
| Shareholders Equity (USD) | -200.20M | ||
| Assets Non-Current | 5.95M | ||
| Total Debt (USD) | 2.88M | ||
| Liabilities Non-Current | 656.44M | ||
| Trade and Non-Trade Payables | 4.00M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 145.00K | ||
| Net Cash Flow from Financing | -106.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -62.02M | ||
| Capital Expenditure | -120.00K | ||
| Issuance (Purchase) of Equity Shares | -236.00K | ||
| Net Cash Flow from Investing | -36.53M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -36.41M | ||
| Net Cash Flow from Operations | -25.38M | ||
| Share Based Compensation | 9.40M | ||